CR20210059A - Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices - Google Patents

Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices

Info

Publication number
CR20210059A
CR20210059A CR20210059A CR20210059A CR20210059A CR 20210059 A CR20210059 A CR 20210059A CR 20210059 A CR20210059 A CR 20210059A CR 20210059 A CR20210059 A CR 20210059A CR 20210059 A CR20210059 A CR 20210059A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical composition
thrombosis
treatment
delivery
methods
Prior art date
Application number
CR20210059A
Other languages
Spanish (es)
Inventor
Michael K Handley
Original Assignee
Marizyme Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marizyme Biotech filed Critical Marizyme Biotech
Publication of CR20210059A publication Critical patent/CR20210059A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4806—Hydrolases (3) acting on peptide bonds (3.4) from animals other than mammals, e.g. snakes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/12036—Type of occlusion partial occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/1204—Type of occlusion temporary occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136—Balloons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A pharmaceutical composition and a method of using the pharmaceutical composition for the treatment of thrombosis are provided. The pharmaceutical composition can include a mixture of proteolytic enzymes, and optionally, additional compounds. The pharmaceutical composition can include an antiaggregatory or anti -thrombotic compound, such as <em>Lisini racemici acetylsalicylase</em>. The method can include administering the pharmaceutical composition to a patient in need thereof, including administration of the pharmaceutical composition to a thrombus until the thrombus is dissolved. The method can also include administering one or more balloon catheters to the patient.
CR20210059A 2018-06-28 2019-06-28 Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices CR20210059A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862691319P 2018-06-28 2018-06-28
PCT/US2019/039878 WO2020006444A1 (en) 2018-06-28 2019-06-28 Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices

Publications (1)

Publication Number Publication Date
CR20210059A true CR20210059A (en) 2021-12-23

Family

ID=68985200

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210059A CR20210059A (en) 2018-06-28 2019-06-28 Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices

Country Status (10)

Country Link
EP (1) EP3813687A4 (en)
JP (1) JP2022525713A (en)
CN (1) CN112638289A (en)
AU (1) AU2019292557A1 (en)
BR (1) BR112021004809A2 (en)
CA (1) CA3110779A1 (en)
CR (1) CR20210059A (en)
EA (1) EA202190494A1 (en)
PE (1) PE20241469A1 (en)
WO (1) WO2020006444A1 (en)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130527A (en) * 1984-07-20 1986-02-12 Kao Corp Thrombolytic agent
AU7278094A (en) * 1994-06-07 1996-01-04 M D Serv Europe S.A. Intravasal thrombolysis
US6022309A (en) * 1996-04-24 2000-02-08 The Regents Of The University Of California Opto-acoustic thrombolysis
FR2797768B1 (en) * 1999-09-01 2003-06-13 Ifremer USE OF A LOW MOLECULAR WEIGHT SULPHATE POLYSACCHARIDE FOR THE PRODUCTION OF A MEDICAMENT ACTIVE AGAINST VASCULAR THROMBOSIS
CN102319266B (en) * 2001-06-18 2014-12-17 海王星技术&生物资源有限公司 Krill and/or seafood extracts for the prevention and/or treatment of cardiovascular disease, arthritis, skin cancer, diabetes, PMS and transdermal delivery
PT1438065E (en) * 2001-10-01 2013-01-24 Matrizyme Pharma Corp Use of collagenase to facilitate guide wire crossing in chronic arterial occlusions
CN1210036C (en) * 2002-06-18 2005-07-13 蚌埠丰原医药科技发展有限公司 New application of aspirin-lysine
SE0303588D0 (en) * 2003-12-30 2003-12-30 Bioactive Polymers Ab C O Lund Surface protection of exposed biological tissues
JP4677557B2 (en) * 2005-05-11 2011-04-27 国立大学法人東北大学 Ultrasonic probe, catheter using the same, and manufacturing method thereof
EP1726301A1 (en) * 2005-05-24 2006-11-29 Flamel Technologies Oral pharmaceutical composition for treating a COX-2 mediated condition
DE102005042338B4 (en) * 2005-09-06 2007-07-05 Siemens Ag catheter device
AR059012A1 (en) * 2006-01-13 2008-03-05 Aker Biomarine Asa EXTRACTS DERIVED FROM KRILL
WO2012095702A1 (en) * 2011-01-13 2012-07-19 Medestea Internazionale S.P.A. A composition for the regeneration of atrophic tissues
US10687832B2 (en) * 2013-11-18 2020-06-23 Koninklijke Philips N.V. Methods and devices for thrombus dispersal
DE202015002060U1 (en) * 2015-03-17 2015-11-25 Gerhard-Friedrich Horak Infusion and aspiration catheter (IAC) (catheter for removal of thrombi and application of drugs)
IL305537B2 (en) * 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US20180161552A1 (en) * 2016-12-13 2018-06-14 Boston Scientific Scimed, Inc. Thrombolysis catheter system

Also Published As

Publication number Publication date
BR112021004809A2 (en) 2021-06-22
CN112638289A (en) 2021-04-09
AU2019292557A1 (en) 2021-04-01
EA202190494A1 (en) 2021-12-09
WO2020006444A1 (en) 2020-01-02
EP3813687A4 (en) 2022-03-23
EP3813687A1 (en) 2021-05-05
JP2022525713A (en) 2022-05-19
CA3110779A1 (en) 2020-01-02
PE20241469A1 (en) 2024-07-15

Similar Documents

Publication Publication Date Title
MX2021007970A (en) 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof.
MX2020007853A (en) Pharmaceutical compositions for treating cystic fibrosis.
PH12019502288A1 (en) Ask1 inhibitor compounds and uses thereof
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
PH12021551635A1 (en) Hexone glucokinase inhibitor and use thereof
MX2023003627A (en) 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer.
CA3011103A1 (en) Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
MY201382A (en) Pde9 inhibitor and use thereof
MX2020013785A (en) Pyridopyrimidine derivative, preparation method therefor and medical use thereof.
MX2021010106A (en) Inhibitors of integrated stress response pathway.
MY202884A (en) Compounds useful in hiv therapy
PH12021551232A1 (en) Haloallylamine compounds and application thereof
MX2024009403A (en) Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2023012723A (en) Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases.
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
NZ752750A (en) Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2021022058A3 (en) Antiarrhythmic formulation
MX2020014262A (en) Pharmaceutical composition containing poorly-soluble basic medicine.
EP4295906A3 (en) Treatment of restenosis using temsirolimus
MX2020013692A (en) Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma.
MX2022012001A (en) Preventative treatment of migraine.
MY193963A (en) Composition for treating joint diseases and kit containing same